Basel – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its Caponago, Italy site, targeting total production capacity of up to 500 million injectable units per year.

Pittsburgh – September 15, 2026 -- MSA Safety has launched the A1X, a next-generation WinGrip vacuum anchor that weighs 7 kg -- 35% lighter than its predecessor -- and cuts its diameter to 350 mm from 480 mm, aiming to speed up aircraft maintenance checks.

Dublin – September 15, 2026 -- ZeroRisk, an Irish cybersecurity firm serving payment providers, has closed a $10 million Series A funding round led by MiddleGame Ventures, with participation from existing backer Elkstone.

Berlin – September 15, 2026 -- Midea has sold more than 10 million R290 air conditioners worldwide since 2018, cutting an estimated 5.2 million tonnes of CO2-equivalent emissions, the company said at IFA 2026 in Berlin.

Berlin – September 15, 2026 -- Rokid unveiled AIUI Studio at IFA Berlin 2026, a browser-based development platform that lets users build AI agent applications for its smart glasses without writing code.

Amsterdam – September 15, 2026 -- SMiT will debut a CI+ 2.0 USB dongle embedding Ultra-Wideband (UWB) technology at IBC2026, targeting Pay-TV operators seeking consent-based audience measurement on the main screen.

Berlin – September 15, 2026 -- Rokid unveiled AIUI Studio at IFA Berlin 2026, a browser-based development platform that lets creators build and publish spatial AI applications for its AI Glasses without writing code.

Berlin – September 15, 2026 -- Rokid unveiled AIUI Studio at IFA Berlin 2026, a browser-based development platform that lets users build AI applications for its smart glasses without writing code.

Stokke, Norway – September 15, 2026 -- Yutong Bus opened its first comprehensive service center in Europe on September 8 in Stokke, Norway, a 38,941-square-meter facility designed to support battery-electric bus fleets across the full vehicle lifecycle.

Durham – September 15, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in RESCUE HF-CS, a global Phase 3 trial testing istaroxime as a potential first-ever approved drug for heart-failure-related cardiogenic shock, a condition with no FDA-approved treatment.

Trial to enroll 600 patients across four continents

The study will recruit approximately 600 patients at clinical sites in the United States, Europe, China and South America. It builds on four completed Phase 2 trials that enrolled more than 350 patients.